Nab-paclitaxel, docetaxel, or solvent-based paclitaxel in metastatic breast cancer: a cost-utility analysis from a Chinese health care perspective

• Main Authors: Dranitsaris G (Author), Yu B (Author), King J (Author), Kaura S (Author), Zhang A (Author)
• Format: Book
• Published: Dove Medical Press, 2015-05-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

George Dranitsaris,1 Bo Yu,2 Jennifer King,3 Satyin Kaura,3 Adams Zhang3 1Augmentium Pharma Consulting Inc., Toronto, ON, Canada; 2Fudan University Shanghai Cancer Center, Shanghai, People's Republic of China; 3Celgene Corporation, Summit, NJ, USA Background: Paclitaxel and docetaxel are com...